These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10965742)

  • 1. [Clinical evaluation of basic fetoprotein in bladder cancer].
    Ichikawa T; Nakayama Y; Yamada D; Saegusa M; Asano S; Aramaki K
    Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):579-83. PubMed ID: 10965742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies].
    Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y
    Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer].
    Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical study of urine basic fetoprotein and urine polyamine as tumor markers in epithelial cancer of the urinary tract.
    Sato D; Kase T; Tajima M; Sawamura Y; Matsushima M
    Int J Urol; 2001 May; 8(5):217-21. PubMed ID: 11328421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
    Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
    J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
    Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
    Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH
    Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K
    J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
    Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
    Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
    Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
    J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.